At the time of writing, Harmony Biosciences Holdings Inc [HRMY] stock is trading at $32.83, up 6.18%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The HRMY shares have lost -3.07% over the last week, with a monthly amount glided 0.89%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Harmony Biosciences Holdings Inc [NASDAQ: HRMY] stock has seen the most recent analyst activity on June 21, 2024, when Citigroup initiated its Buy rating and assigned the stock a price target of $48. Previously, BofA Securities downgraded its rating to Underperform on January 02, 2024, and kept the price target unchanged to $30. On September 25, 2023, downgrade downgraded it’s rating to Sell and revised its price target to $31 on the stock. Berenberg started tracking the stock assigning a Buy rating and suggested a price target of $59 on September 07, 2023. BofA Securities initiated its recommendation with a Neutral and recommended $35 as its price target on April 20, 2023. Jefferies upgraded its rating to Buy for this stock on October 14, 2022, and upped its price target to $61. In a note dated October 14, 2022, Janney upgraded an Buy rating on this stock and boosted its target price from $57 to $61.
For the past year, the stock price of Harmony Biosciences Holdings Inc fluctuated between $18.61 and $39.26. Currently, Wall Street analysts expect the stock to reach $51.5 within the next 12 months. Harmony Biosciences Holdings Inc [NASDAQ: HRMY] shares were valued at $32.83 at the most recent close of the market. An investor can expect a potential return of 56.87% based on the average HRMY price forecast.
Analyzing the HRMY fundamentals
According to Harmony Biosciences Holdings Inc [NASDAQ:HRMY], the company’s sales were 617.51M for trailing twelve months, which represents an 29.79% jump. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at 0.27%, Pretax Profit Margin comes in at 0.25%, and Net Profit Margin reading is 0.21%. To continue investigating profitability, this company’s Return on Assets is posted at 0.16, Equity is 0.27 and Total Capital is 0.25. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.35.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 31.07 points at the first support level, and at 29.30 for the second support level. However, for the 1st resistance point, the stock is sitting at 34.75, and for the 2nd resistance point, it is at 36.66.
Ratios To Look Out For
It is important to note that Harmony Biosciences Holdings Inc [NASDAQ:HRMY] has a current ratio of 3.11. As well, the Quick Ratio is 3.07, while the Cash Ratio is 2.16. Considering the valuation of this stock, the price to sales ratio is 3.02, the price to book ratio is 3.62 and price to earnings (TTM) ratio is 14.17.
Transactions by insiders
Recent insider trading involved Dierks Jeffrey, CHIEF COMMERCIAL OFFICER, that happened on Mar 15 ’24 when 11979.0 shares were sold. CHIEF COMMERCIAL OFFICER, Dierks Jeffrey completed a deal on Mar 08 ’24 to sell 194.0 shares.
